Abstract
Background: Both the administration of adefovir dipivoxil and the elevation of primary parathyroid hormone can result in serum electrolyte abnormalities and the development of metabolic bone disease. Adefovir dipivoxil-induced osteomalacia is a clinical disease that is rarely seen and often leads to misdiagnosis. Case presentation: In this case, the patient developed osteomalacia due to renal tubular toxicity caused by chronic use of adefovir dipivoxil. The drug indirectly affected the secretion of parathyroid hormone (PTH). Coincidentally, the patient also had a tumor below the thyroid, leading to a misdiagnosis. Conclusion: Osteomalacia caused by adefovir dipivoxil is a clinically rare disease, and it is important not to overlook it as it may lead to misdiagnosis. Hence, in cases where laboratory tests reveal abnormal parathyroid hormone levels, it is crucial to inquire about the patient s detailed medication history. This is applicable even in situations where there is evidence suggesting primary hyperparathyroidism.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
